Drugs / MMRV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07406360 Comparator | May 2026 → Feb 2028 expected | measles | GlaxoSmithKline | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMRV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07406360 ↗ |
| Modality | Vaccine | “Merck's measles, mumps, rubella and varicella (ProQuad) vaccine” NCT07406360 ↗ |
| Route | Intramuscular | “One dose of MMRV administered intramuscularly.” NCT07406360 ↗ |